Key Highlights
- Nurix closed at $26.10 on October 20, up 4.89% on the day and 17.78% over the week.
- ORIC closed at $13.78, up 8.33% on the day and 17.98% over the week.
- Nurix reported quarterly revenue of $673.1 million, including $653.2 million recognized from Roche's upfront payment.
- Nurix held $1.1 billion in cash and marketable securities at August 31, with a runway into the second half of 2029.
- ORIC held $387.6 million in cash and investments at June 30, with a runway into the second half of 2028.
Why Are Nurix Therapeutics and ORIC Pharmaceuticals Stocks Both Up 18% This Week, and What Are Investors Missing?
Nurix Therapeutics (NASDAQ:NRIX) and ORIC Pharmaceuticals (NASDAQ:ORIC) each gained about 18% over the week, and both are clinical-stage cancer developers with long cash runways. What investors may be missing is that Nurix's recent quarter was lifted by $653.2 million of one-time revenue recognized from Roche's upfront payment, while both companies hold long cash runways, into the second half of 2029 for Nurix and the second half of 2028 for ORIC. Nurix closed at $26.10 on October 20, up 4.89% on the day and 17.78% over the week, for a market capitalization of about $2.85 billion. ORIC closed at $13.78, up 8.33% on the day and 17.98% over the week, valued at about $1.43 billion.
Over the past month Nurix has gained 3.08% and ORIC 7.57%. Nurix has a dated disclosure just before the rally in its fiscal third-quarter report, while no announcement was identified for ORIC in the week of its advance.
Why Is Nurix Stock Rising After a $549.8 Million Quarterly Profit?
Nurix develops targeted protein degraders for cancer and immune disease, with bexobrutideg, a BTK degrader, as its lead program. It released fiscal third-quarter results in mid-October for the quarter ended August 31. Revenue was $673.1 million against $7.9 million a year earlier, of which $653.2 million was recognized from the $700 million upfront payment in the company's collaboration with Roche. Net income was $549.8 million, or $4.73 per diluted share, compared with a net loss of $86.4 million a year earlier.
The profit is a function of deal accounting rather than operations. Research and development expenses fell to $79.3 million from $86.1 million, while general and administrative expenses rose to $34.4 million from $13.2 million on one-time deal costs. Milestone revenue of about $27 million came from three partners, at $10 million, $7 million and $10 million. The company did not provide numeric guidance beyond its cash runway.
Cash and marketable securities were $1.1 billion at August 31, and the company said that funds operations into the second half of 2029. Under the Roche agreement, costs of bexobrutideg are shared 40% by Nurix and 60% by Roche, US profits are shared equally and Nurix receives royalties outside the United States. The first patient has been dosed in the Phase 3 DAYBreak CLL-306 study, which compares bexobrutideg with pirtobrutinib in about 620 patients with chronic lymphocytic leukemia.
Nurix also discontinued development of NX-2127. A STAT6 degrader partnered with another company has entered Phase 1, with about $139 million earned to date and about $455 million of additional payments eligible. An IRAK4 degrader partnered with a third company remains in Phase 1, a combination study with venetoclax is recruiting, and expansion cohorts for NX-1607 are under way. The date of the next earnings report, for the fiscal year ending November 30, had not been announced in the sources reviewed.
What Could Move ORIC Pharmaceuticals After the October ESMO Presentation?
ORIC develops rinzimetostat, a PRC2 inhibitor for prostate cancer, and enozertinib, an EGFR inhibitor for lung cancer. The company has no revenue. In its second-quarter report on August 3 it posted a net loss of $41.5 million, or $0.38 per share, and said cash and investments were $387.6 million at June 30. That total includes $59.9 million of at-the-market proceeds raised in the first quarter, and the company said it funds operations into the second half of 2028.
The company has started the Phase 3 Himalayas-1 study of rinzimetostat in metastatic castration-resistant prostate cancer, which plans to enroll about 600 patients at more than 250 sites. Bayer supplies darolutamide for the combination at no cost, and ORIC retains global rights to rinzimetostat.
The nearest data event was planned for October. ORIC said it would present first-line enozertinib monotherapy data in patients with atypical EGFR mutations at the ESMO congress, but no release confirming the presentation was found, so the link to the stock's move is unconfirmed. Further updates are scheduled for the second half of 2026, including exon 20 monotherapy data, data from a subcutaneous amivantamab combination and a rinzimetostat program update. A decision on a registrational trial for enozertinib is expected to follow those clinical updates.
The date of the third-quarter report had not been confirmed in the sources reviewed.
How Do Nurix and ORIC Compare on Cash Relative to Market Value?
Nurix is the larger company by market value at about $2.85 billion against about $1.43 billion for ORIC. Its $1.1 billion of cash and marketable securities equals about 39% of its market value, while ORIC's $387.6 million equals about 27% of its value.
At ORIC's second-quarter net loss of $41.5 million, its cash would cover about 9.3 quarters, consistent with the runway into the second half of 2028 that the company cited. Nurix does not give a comparable loss figure for the latest quarter because its $549.8 million profit reflects the Roche payment, but its research and development spending of $79.3 million and general and administrative spending of $34.4 million give a sense of the underlying cost base.
Both are running or starting Phase 3 programs, with Nurix's DAYBreak study in leukemia already dosing and ORIC's Himalayas-1 study in prostate cancer having started. Their weekly gains of 17.78% and 17.98% are almost identical, though only Nurix has a dated disclosure just before the rally.
Combined, the two companies hold about $1.49 billion of cash and securities against a combined market value of about $4.28 billion, or roughly 35%.
How Do Nurix's One-Time Gain and ORIC's Data Calendar Shape the Next Quarter?
Nurix's profit will not repeat, so the next reading on its business will come from operating expenses, milestone receipts and Phase 3 enrollment in the leukemia study. ORIC's calendar is data-driven, with the ESMO enozertinib presentation and the second-half updates as the next checkpoints. Both companies carry cash runways that stretch into 2028 and 2029, which limits near-term financing risk.






Please wait processing your request...